PATIENT WEBSITE

FOR us HEALTHCARE professionals only



Dolphin image for AKYNZEO

One dose* for 5 days of CINV prevention

See Dosing

Efficacy across both acute and delayed CINV

SEE THE DATA

AKYNZEO® has a demonstrated safety profile in CINV patients

Safety was evaluated in >1000 patients over 4500 cycles1

Adverse reactions occurring in ≥3% of patients receiving AKYNZEO and cisplatin-based chemotherapy regimens1

Adverse Reactions AKYNZEO
(n=136)
Oral Palonosetron
0.5 mg (n=136)
Dyspepsia 4% 2%
Fatigue 4% 2%
Constipation 3% 1%
Erythema 3% 2%

A single-cycle study of patients receiving cisplatin-based, highly emetogenic chemotherapy (AKYNZEO, n=136).1

Adverse reactions occurring in ≥3% of cancer patients receiving AKYNZEO and AC-based chemotherapy regimens1

Adverse Reactions AKYNZEO
(n=725)
Oral Palonosetron
0.5 mg (n=725)
Headache 9% 7%
Asthenia 8% 7%
Fatigue 7% 5%

A study of patients receiving AC-based chemotherapy treatment. 725 patients were treated with AKYNZEO during Cycle 1; 635 of these patients continued for up to 8 cycles in a multiple-cycle extension.

One dose* for 5 days of CINV prevention

See Dosing

Efficacy across both acute and delayed CINV

LEARN MORE
Reference: 1. AKYNZEO® (netupitant/palonosetron) capsules Full Prescribing Information.